KR101287280B1 - 태반 성장 인자 매개된 전이 및/또는 혈관신생의 억제 - Google Patents

태반 성장 인자 매개된 전이 및/또는 혈관신생의 억제 Download PDF

Info

Publication number
KR101287280B1
KR101287280B1 KR1020087009357A KR20087009357A KR101287280B1 KR 101287280 B1 KR101287280 B1 KR 101287280B1 KR 1020087009357 A KR1020087009357 A KR 1020087009357A KR 20087009357 A KR20087009357 A KR 20087009357A KR 101287280 B1 KR101287280 B1 KR 101287280B1
Authority
KR
South Korea
Prior art keywords
plgf
antibody
peptide
tumor
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087009357A
Other languages
English (en)
Korean (ko)
Other versions
KR20080055932A (ko
Inventor
데이비드 엠 골든버그
시엔 싱 창
앨리스 피 테일러
Original Assignee
이뮤노메딕스, 인코오포레이티드
센터 포 몰레큘러 메디신 앤드 이뮤놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤노메딕스, 인코오포레이티드, 센터 포 몰레큘러 메디신 앤드 이뮤놀로지 filed Critical 이뮤노메딕스, 인코오포레이티드
Publication of KR20080055932A publication Critical patent/KR20080055932A/ko
Application granted granted Critical
Publication of KR101287280B1 publication Critical patent/KR101287280B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
KR1020087009357A 2005-10-19 2006-10-16 태반 성장 인자 매개된 전이 및/또는 혈관신생의 억제 Expired - Fee Related KR101287280B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72829205P 2005-10-19 2005-10-19
US60/728,292 2005-10-19
PCT/US2006/040431 WO2007047609A2 (en) 2005-10-19 2006-10-16 INHIBITION OF PLACENTA GROWTH FACTOR (PlGF) MEDICATED METASTASIS AND/OR ANGIOGENESIS

Publications (2)

Publication Number Publication Date
KR20080055932A KR20080055932A (ko) 2008-06-19
KR101287280B1 true KR101287280B1 (ko) 2013-07-23

Family

ID=37963183

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087009357A Expired - Fee Related KR101287280B1 (ko) 2005-10-19 2006-10-16 태반 성장 인자 매개된 전이 및/또는 혈관신생의 억제

Country Status (8)

Country Link
US (3) US7642239B2 (https=)
EP (1) EP1937724A4 (https=)
JP (1) JP5498018B2 (https=)
KR (1) KR101287280B1 (https=)
CN (2) CN101534865A (https=)
AU (1) AU2006304418B2 (https=)
CA (1) CA2625992C (https=)
WO (1) WO2007047609A2 (https=)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8658773B2 (en) 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US7878978B2 (en) * 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
US8067006B2 (en) 2005-04-06 2011-11-29 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
WO2008073828A2 (en) * 2006-12-08 2008-06-19 Northwestern University Compositions and methods for magnetic resonance imaging contrast agents
US20080299077A1 (en) * 2007-06-01 2008-12-04 Nevada Cancer Institute Isolation and growth of stem cells from hemangiomas
WO2008151021A1 (en) * 2007-06-01 2008-12-11 Nevada Cancer Institute Isolation and growth of stem cells from hemangiomas
WO2009080764A2 (en) * 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
US8034396B2 (en) * 2008-04-01 2011-10-11 Tyco Healthcare Group Lp Bioadhesive composition formed using click chemistry
EP2116555A1 (en) * 2008-05-08 2009-11-11 Bayer Schering Pharma Aktiengesellschaft Use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment of Hodgkin lymphoma
MX2010012454A (es) * 2008-05-16 2011-03-29 Corthera Inc Star Metodo para promover la curacion de heridas.
CN102224419A (zh) * 2008-06-18 2011-10-19 雅培制药有限公司 PlGF-1搭配诊断法和产物
US20100004306A1 (en) * 2008-06-18 2010-01-07 Abbott Laboratories PIGF-1 Assay and kits and components thereof
US8741287B2 (en) * 2008-06-18 2014-06-03 Abbott Laboratories PlGF-1 assay and kits and components thereof
CN102239178B (zh) 2008-10-02 2017-06-23 Vib研究所 抑制PlGF以治疗费城染色体阳性白血病
US8940331B2 (en) * 2008-11-22 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Hydrogels, methods of making hydrogels, methods of using hydrogels, and methods of isolating, trapping, attracting, and/or killing cancer cells
BRPI0918211A2 (pt) * 2008-12-23 2015-12-08 Genentech Inc métodos de identificação de um paciente, métodos de predição da responsividade de um paciente, métodos de monitoramento, métodos de otimização da eficácia terapêutica e kit para detecção do níveis de expressão de p1gf
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
US20160095939A1 (en) 2014-10-07 2016-04-07 Immunomedics, Inc. Neoadjuvant use of antibody-drug conjugates
WO2010096654A1 (en) 2009-02-21 2010-08-26 Tyco Healthcare Group Lp Medical devices having activated surfaces
US8968733B2 (en) * 2009-02-21 2015-03-03 Sofradim Production Functionalized surgical adhesives
EP2398850B1 (en) 2009-02-21 2018-08-22 Sofradim Production Medical devices with an activated coating
CA2753162A1 (en) 2009-02-21 2010-08-26 Sofradim Production Amphiphilic compounds and self-assembling compositions made therefrom
US8512728B2 (en) 2009-02-21 2013-08-20 Sofradim Production Method of forming a medical device on biological tissue
US8535477B2 (en) * 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
US8877170B2 (en) * 2009-02-21 2014-11-04 Sofradim Production Medical device with inflammatory response-reducing coating
EP2398584A2 (en) 2009-02-21 2011-12-28 Sofradim Production Apparatus and method of reaching polymers by exposure to uv radiation to produce injectable medical devices
AU2010215931A1 (en) 2009-02-21 2011-10-13 Covidien Lp Medical devices having activated surfaces
US8969473B2 (en) 2009-02-21 2015-03-03 Sofradim Production Compounds and medical devices activated with solvophobic linkers
AU2010215196B2 (en) 2009-02-21 2015-04-16 Covidien Lp Crosslinked fibers and method of making same by extrusion
WO2010095047A2 (en) 2009-02-21 2010-08-26 Sofradim Production Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
CA2753171A1 (en) 2009-02-21 2010-08-26 Sofradim Production Crosslinked fibers and method of making same using uv radiation
US8663689B2 (en) * 2009-02-21 2014-03-04 Sofradim Production Functionalized adhesive medical gel
WO2010097800A1 (en) * 2009-02-26 2010-09-02 Muhammad Abdulrazik Synergistic combination of bioactive compounds for lowering of intraocular pressure
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
EP2518078B1 (en) * 2009-12-15 2020-05-20 Choe, Muhyeon Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an affinity domain of a type specifically binding to protein monomers
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
US9272074B2 (en) * 2010-03-25 2016-03-01 Sofradim Production Surgical fasteners and methods for sealing wounds
US8795331B2 (en) 2010-03-25 2014-08-05 Covidien Lp Medical devices incorporating functional adhesives
AU2011276443A1 (en) 2010-06-29 2013-01-31 Covidien Lp Microwave-powered reactor and method for in situ forming implants
WO2012001532A2 (en) 2010-07-01 2012-01-05 Sofradim Production Medical device with predefined activated cellular integration
WO2012001820A1 (en) * 2010-07-02 2012-01-05 National University Corporation Tokyo University Of Agriculture And Technology Psa binding aptamer and method for diagnosis of prostate cancer
WO2012014080A2 (en) 2010-07-27 2012-02-02 Sofradim Production Polymeric fibers having tissue reactive members
CN102028955A (zh) * 2010-08-09 2011-04-27 华中科技大学同济医学院附属同济医院 一种用于肿瘤基因干预的新型靶向复合物
CN102680619A (zh) * 2011-03-09 2012-09-19 北京康华源医药信息咨询有限公司 一种胶体金属定量检测技术及其用途
CN102286101B (zh) * 2011-08-08 2013-05-08 常州亚当生物技术有限公司 抗VEGF单克隆抗体Fab片段Vasculizumab及其应用
US9180167B2 (en) 2011-08-26 2015-11-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Activators of CXCR3 for the treatment of angiopathies of the eye
CN102505180A (zh) * 2011-09-16 2012-06-20 彭可扬 一种用于防治室内微生物污染的负载伊曲康唑-溶菌酶电纺纤维膜
AU2012321082B2 (en) * 2011-12-01 2015-03-12 Oxurion NV Improving trabeculectomy outcome
CN103087196B (zh) * 2012-06-26 2016-12-21 青岛大学附属医院 胞壁酰二肽-抗cd20免疫偶联物制备方法及应用
CN104379169A (zh) 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
CN107753954A (zh) * 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
WO2015109329A1 (en) 2014-01-17 2015-07-23 Mimedx Group, Inc. Method for inducing angiogenesis
US9895419B2 (en) 2014-01-21 2018-02-20 University of Pittsburgh—of the Commonwealth System of Higher Education Goblet cell replacement therapy
JP6447933B2 (ja) 2014-02-21 2019-01-09 アイビーシー ファーマスーティカルズ，インコーポレイテッド Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
CN104109670B (zh) * 2014-03-12 2018-01-05 首都医科大学附属北京安定医院 一种双链siRNA分子及其应用
TWI625123B (zh) 2014-03-31 2018-06-01 分離胎盤中雌激素之方法
EP3160504B1 (en) 2014-06-24 2020-09-16 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
KR101551306B1 (ko) * 2015-03-23 2015-09-09 아주대학교산학협력단 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도
US11000603B2 (en) 2015-04-14 2021-05-11 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
AU2016252771B2 (en) 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
JP6980980B2 (ja) 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
CN105669871A (zh) * 2016-04-19 2016-06-15 中国药科大学 一种胸腺肽α1的融合蛋白
CN109195992A (zh) * 2016-04-29 2019-01-11 本康生物制药（深圳）有限公司 多特异性结合偶联物、相关的药物组合物及应用
CN107362370B (zh) * 2016-05-13 2022-07-26 国家纳米科学中心 一种基于金纳米簇联合NGF siRNA治疗胰腺癌的方法
EP3502142B1 (en) 2016-06-22 2021-10-27 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Bispecific antibody and antibody conjugate for tumour therapy and use thereof
CN106596911B (zh) * 2016-12-16 2019-07-19 石河子大学 一种证明缝隙连接在高血压炎症反应中的作用的试验方法
EP3599250A4 (en) 2017-01-24 2021-06-09 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. ANTIBODY CONJUGATE AND RELATED PHARMACEUTICAL COMPOSITION AND APPLICATION
WO2019101812A2 (en) * 2017-11-22 2019-05-31 Firmenich Sa Method of identifying laundry malodor, moldy malodor and/or sweat malodor modulating compounds
CN110326584B (zh) * 2019-07-04 2020-06-19 西安交通大学 一种p物质诱导的过敏性哮喘动物模型的构建方法和筛选药物的方法
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
WO2022239720A1 (ja) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 抗原への結合親和性を低減させた抗体
CN114404367B (zh) * 2021-12-29 2023-02-21 中山大学附属第一医院 一种通过对病变细胞靶向分布的纳米载体及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180286A1 (en) * 2000-05-12 2003-09-25 Peter Carmeliet Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage
KR20050047032A (ko) * 2003-11-13 2005-05-19 한미약품 주식회사 면역글로불린 단편을 이용한 단백질 결합체 및 그의제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
GB9723780D0 (en) 1997-11-12 1998-01-07 Univ Manchester Regulation of ocular angiogenesis
US20040053837A1 (en) 1998-09-30 2004-03-18 Ludwig Institute For Cancer Research Composition and method for modulating vasculogenesis or angiogenesis
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US7105168B1 (en) 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
US7727971B2 (en) 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
US6930089B2 (en) 2000-02-04 2005-08-16 D. Collen Research Foundation Vzw Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke
EP1272208B1 (en) 2000-04-12 2011-10-05 VIB vzw Use of vegf 165 and homologues to treat neuron disorders
AU2002241801A1 (en) * 2000-11-07 2002-06-18 Gpc Biotech Inc. Methods and reagents for isolating angiogenic modulators
DE60234100D1 (de) 2001-04-24 2009-12-03 Vlaams Interuniv Inst Biotech Verwendung von "hypoxia inducible factor 2alpha" zur behandlung von "neonatal respiratory distress syndrome"
JP2003012541A (ja) * 2001-06-07 2003-01-15 Daiichi Fine Chemical Co Ltd 血管新生阻害剤
JP2005535634A (ja) 2002-06-28 2005-11-24 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー（ヴェーイーベー・ヴェーゼットウェー） Ｆｌｔ−１に対する抗体の骨粗鬆症の処置のための使用
MX2007011735A (es) * 2005-03-24 2008-03-14 Thrombogenics Nv Anticuerpo anti-plgf novedoso.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030180286A1 (en) * 2000-05-12 2003-09-25 Peter Carmeliet Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage
KR20050047032A (ko) * 2003-11-13 2005-05-19 한미약품 주식회사 면역글로불린 단편을 이용한 단백질 결합체 및 그의제조방법

Also Published As

Publication number Publication date
AU2006304418B2 (en) 2013-03-28
US20070087001A1 (en) 2007-04-19
JP5498018B2 (ja) 2014-05-21
US7932212B2 (en) 2011-04-26
US20110189268A1 (en) 2011-08-04
CA2625992A1 (en) 2007-04-26
WO2007047609A3 (en) 2009-03-19
US20100216662A1 (en) 2010-08-26
EP1937724A4 (en) 2009-11-04
CA2625992C (en) 2014-05-27
CN101534849A (zh) 2009-09-16
CN101534865A (zh) 2009-09-16
US7642239B2 (en) 2010-01-05
AU2006304418A1 (en) 2007-04-26
EP1937724A2 (en) 2008-07-02
KR20080055932A (ko) 2008-06-19
WO2007047609A2 (en) 2007-04-26
JP2009514813A (ja) 2009-04-09

Similar Documents

Publication Publication Date Title
KR101287280B1 (ko) 태반 성장 인자 매개된 전이 및/또는 혈관신생의 억제
JP2024161402A (ja) 抗ｔｌ１ａモノクローナル抗体の中和
JP6783797B2 (ja) 抗がん融合ポリペプチド
JP2022104941A (ja) ヒト化抗ｃｄ７３抗体
JP5548616B2 (ja) Ｖｅｇｆｒ−１／ｎｒｐ−１標的化ペプチド
US7914780B1 (en) Aminopeptidase A (APA) targeting peptides for the treatment of cancer
BRPI1006141B1 (pt) Composições de anticorpo modificado, métodos para preparar e usar as mesmas
JP2006519163A (ja) 癌転移および癌転移に伴なう骨量減少を防止および処置するための方法
US20060199248A1 (en) Q3 SPARC deletion mutant and uses thereof
TW200934512A (en) PLEXIND1 agonists and their use
WO2021197359A1 (zh) 一种构建多特异性抗体的平台
WO2023174312A1 (zh) 抗人pd-l1和tlr7双靶向纳米抗体偶联药物及其在抗肿瘤中的应用
WO2023066389A1 (zh) 靶向pd-1的双特异性抗体、及其制备和应用
WO2025118472A1 (zh) 一种抗met/egfr双特异性抗体及其药物偶联物
US20050260132A1 (en) Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
EP3145545B1 (en) Bak binding proteins
TWI886446B (zh) 重組抗體及其用途
CN120058937B (zh) 一种靶向lgr4的纳米抗体nb21及其在抗肥胖治疗中的应用
CN101017166A (zh) 人rtn4b蛋白在制备抗肿瘤药物中的应用
US20240199735A1 (en) Microfibrillar-Associated Protein 5 (MFAP5)-Targeting Monoclonal Antibodies and Methods for Use in Treating Cancer
JP2026506269A (ja) 組換え抗体及びその用途
US20230065416A1 (en) Clathrin-chimetic antibody receptor constructs for immune cell activation therapy in vivo
AU2016202118A1 (en) Carrier immunoglobulins and uses thereof
WO2024027770A1 (zh) 抗ddr2纳米抗体及其应用
CN121494985A (zh) 靶向Trop2/EpCAM的双特异性抗体、抗体偶联药物及其制备方法与应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20160630

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180712

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180712

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000